<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome is a <z:e sem="disease" ids="C0559758" disease_type="Disease or Syndrome" abbrv="">multisystem disorder</z:e> that causes orogenital ulceration, <z:mp ids='MP_0001212'>skin lesions</z:mp> and intraocular <z:mp ids='MP_0001845'>inflammation</z:mp> with <z:hpo ids='HP_0000554'>uveitis</z:hpo> and <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A proportion of affected individuals also develop vascular and central <z:mp ids='MP_0008912'>nervous</z:mp> system manifestations, with significant morbidity and mortality </plain></SENT>
<SENT sid="2" pm="."><plain>Although the aetiopathogenesis of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome is poorly understood, the condition is considered to be driven, at least in part, by autoimmune mechanisms </plain></SENT>
<SENT sid="3" pm="."><plain>Conventional therapy relies on available anti-inflammatory and immunomodulatory agents, and, in view of the paucity of controlled clinical trials, it is to a large extent empirical </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000155'>Oral ulcers</z:hpo> can often be treated by topical application of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>In addition to <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, agents used to treat <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> and significant systemic manifestations include <z:chebi fb="0" ids="23359">colchicine</z:chebi>, thalidomide, <z:chebi fb="2" ids="2948">azathioprine</z:chebi>, <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil, cyclosporin, tacrolimus, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The response to these agents is variable and there is a distinct need for more effective rational treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Over the last decade, a number of open studies have produced promising results using recombinant interferon-alpha preparations </plain></SENT>
<SENT sid="8" pm="."><plain>Evaluating, in a methodical manner, the other new biological agents that are becoming available for the treatment of <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e> offers great promise, not only for effective management but also for providing insights into aetiopathogenesis </plain></SENT>
</text></document>